scholarly journals Liquid Biopsy in Prostate Cancer: A Case for Comprehensive Genomic Characterization of Circulating Tumor Cells

2018 ◽  
Vol 64 (2) ◽  
pp. 251-253 ◽  
Author(s):  
Debasish Boral ◽  
Dario Marchetti
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Genomic Characterization

Abstract LB-236: Genomic characterization of circulating tumor cells in de novo metastatic prostate cancer

2019 ◽  
Author(s):  
Shoujie Chai ◽  
Paymaneh D. Malihi ◽  
Ana M. Apariciop ◽  
Brian F. Chapin ◽  
Matthew Lin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
Genomic Characterization

Abstract LB-236: Genomic characterization of circulating tumor cells in de novo metastatic prostate cancer

2019 ◽  
Author(s):  
Shoujie Chai ◽  
Paymaneh D. Malihi ◽  
Ana M. Apariciop ◽  
Brian F. Chapin ◽  
Matthew Lin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
Genomic Characterization

scholarly journals Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility

2019 ◽  
Vol 65 (1) ◽  
pp. 87-99 ◽  
Author(s):  
Klaus Pantel ◽  
Claudia Hille ◽  
Howard I Scher
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Medical Decision ◽  
Cancer Type ◽  
Castration Resistant Prostate Cancer ◽  
The Past ◽  
Castration Resistant

Abstract BACKGROUND Prostate cancer represents the most common non–skin cancer type in men. Unmet needs include understanding prognosis to determine when intervention is needed and what type, prediction to guide the choice of a systemic therapy, and response indicators to determine whether a treatment is working. Over the past decade, the “liquid biopsy,” characterized by the analysis of tumor cells and tumor cell products such as cell-free nucleic acids (DNA, microRNA) or extracellular vesicles circulating in the blood of cancer patients, has received considerable attention. CONTENT Among those biomarkers, circulating tumor cells (CTCs) have been most intensively analyzed in prostate cancer. Here we discuss recent studies on the enumeration and characterization of CTCs in peripheral blood and how this information can be used to develop biomarkers for each of these clinical contexts. We focus on clinical applications in men with metastatic castration-resistant prostate cancer, in whom CTCs are more often detected and at higher numbers, and clinical validation for different contexts of use is most mature. SUMMARY The overall goal of CTC-based liquid biopsy testing is to better inform medical decision-making so that patient outcomes are improved.

scholarly journals Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Yoon Seok Suh ◽  
Jae Young Joung ◽  
Sung Han Kim ◽  
Ho Kyung Seo ◽  
Jinsoo Chung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Disease Status ◽  
Minimal Invasive ◽  
Future Directions ◽  
Advantages And Disadvantages ◽  
Potential Tool ◽  
Selection Of

Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths worldwide. Additionally, there is concern for overdiagnosis and overtreatment of PC. Thus, selection of an appropriate candidate for active surveillance as well as more accurate and less invasive tools for monitoring advanced PC is required. Circulating tumor cells (CTCs) have emerged as a liquid biopsy tool; there have been several reports on its role, technologies, and applications to various cancers, including PC. Liquid biopsy using CTCs has been gaining attention as a minimal invasive tool for investigation of biomarkers and for prognosis and assessment of response to therapies in patients with PC. Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points. CTC analysis enables detection of genomic alterations, which is drug-targetable, and it is a potential tool for monitoring response to therapeutic agents in patients with PC. This review focuses on the characteristics, technologies for analysis, and advantages and disadvantages of CTCs as a liquid biopsy tool and their application in PC. Finally, we propose future directions of CTCs.

Sign in / Sign up

Export Citation Format

Share Document